Pharma firm in Process of US Food and Drug Administration Approval for Type II Diabetes Clinical Trial

The pioneer in regenerative technologies, Global Institute of Stem Cell Therapy & Research also known as GIOSTAR, made an announcement saying that they are in the middle of getting approval from the US Food and Drug Administration for conducting type II diabetes clinical trials dedicated to developing stem cell-based treatment. Led by the co-founder, as well as, Chairman of GIOSTAR Doctor Anand Srivastava, a group of scientists is doing fu....